Profile data is unavailable for this security.
About the company
Balaxi Pharmaceuticals Limited is an India-based company. The Company operates as an intellectual property right (IPR)-based pharmaceutical company. The Company primarily operates in frontier markets across Latin America and Africa. The Company is focusing on frontier markets, with a growing portfolio of drugs across multiple therapeutic segments. It has a portfolio across multiple therapeutic segments, stock & sell models, and supplies branded and generic medicines. The Company’s products include Anti-biotic, Analgesic, Medical Device, Vitamins, Anti-Malaria, Erectile Dysfunction, Hypertension, Anti-Asthma, Steroid, Anti-Helminthic, Anti-Ulcer, Hygiene, Anticholinergic, Dietary Supplement, Diuretic, Hormone, Anti-Emetic, Bronchodilator, Local Anesthetic, Anemia, Anti-Diarrhea, Antihistamine, Hypotension, Antacid, Anti-Tuberculosis, Insect Repellents and Laxative. Its subsidiary is Balaxi Global DMCC, Dubai.
- Revenue in INR (TTM)2.62bn
- Net income in INR-52.21m
- Incorporated1942
- Employees51.00
- LocationBalaxi Pharmaceuticals LtdPlot No: 409, 3rd Floor,Maps TowersJubilee Hills,Road No:81, HyderabadHYDERABAD 500096IndiaIND
- Phone+91 4 023555300
- Fax+91 4 023558085
- Websitehttps://balaxipharma.in/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Navamedic ASA | 3.99bn | 29.75m | 4.62bn | 10.00 | 155.48 | 2.65 | 37.66 | 1.16 | 0.2187 | 0.2187 | 29.61 | 12.84 | 1.13 | 3.39 | 6.24 | -- | 0.8409 | 0.0724 | 1.29 | 0.1177 | 38.88 | 38.33 | 0.7449 | 0.0704 | 0.5558 | 1.85 | 0.4069 | -- | 33.98 | 22.72 | -87.04 | 0.3123 | 59.60 | -- |
| Kim Forest Enterprise Co Ltd | 1.08bn | -346.37m | 5.11bn | -- | -- | 3.48 | -- | 4.74 | -2.85 | -2.85 | 8.89 | 11.29 | 0.4986 | 3.34 | 4.31 | -- | -16.02 | -0.8245 | -19.78 | -1.06 | 13.15 | 31.99 | -32.14 | -1.25 | 1.19 | -82.43 | 0.2664 | -- | -38.11 | 12.36 | -341.58 | -- | -8.51 | -- |
| Sinco Pharmaceuticals Holdings Ltd | 29.31bn | 488.74m | 5.14bn | 278.00 | 10.53 | 0.7098 | 7.62 | 0.1755 | 0.0225 | 0.0225 | 1.35 | 0.3339 | 1.53 | 22.60 | 5.73 | 9,875,025.00 | 2.56 | 6.48 | 6.55 | 20.22 | 12.73 | 14.79 | 1.67 | 3.86 | 1.08 | 28.20 | 0.2859 | 7.21 | 11.82 | 21.66 | -39.03 | -- | 123.63 | -- |
| Hyphens Pharma International Ltd | 10.56bn | 530.43m | 5.65bn | 440.00 | 10.65 | 1.45 | 8.02 | 0.5347 | 0.0277 | 0.0277 | 0.5513 | 0.2037 | 1.45 | 4.65 | 4.89 | 387,715.90 | 7.29 | 8.35 | 12.10 | 14.01 | 36.29 | 37.06 | 5.03 | 5.65 | 1.35 | -- | 0.0939 | 33.00 | 5.10 | 7.12 | -24.52 | 9.63 | -18.70 | 9.35 |
| Harima-Kyowa Co., LTD. | 32.96bn | 752.79m | 6.15bn | 197.00 | 8.07 | 0.4706 | 7.89 | 0.1867 | 261.75 | 261.75 | 11,459.40 | 4,490.24 | 1.91 | 23.79 | 5.51 | -- | 4.36 | 4.39 | 5.70 | 5.87 | 11.57 | 11.73 | 2.28 | 2.23 | 2.22 | -- | 0.0131 | 17.15 | 2.37 | 5.01 | 1.10 | 3.25 | 34.30 | 3.44 |
| Able View Global Inc | 12.41bn | 786.54m | 6.30bn | 98.00 | 8.11 | 6.71 | 7.83 | 0.5079 | 0.2229 | 0.2229 | 3.52 | 0.2695 | 2.72 | 6.20 | 8.37 | 1,520,406.00 | 17.80 | -- | 30.88 | -- | 24.84 | -- | 6.54 | -- | 1.99 | 7.90 | 0.2017 | -- | 2.58 | -- | 23.46 | -- | -- | -- |
| Natural Health Trends Corp. | 3.58bn | 41.57m | 6.74bn | 138.00 | 161.87 | 2.06 | 124.18 | 1.88 | 0.0434 | 0.0434 | 3.75 | 3.42 | 0.582 | 2.24 | -- | 311,695.70 | 0.6751 | -0.5398 | 0.9333 | -0.7099 | 74.30 | 74.06 | 1.16 | -0.9571 | 2.77 | -- | 0.00 | -- | -10.60 | -25.54 | 81.47 | -54.86 | -26.47 | 6.64 |
| Balaxi Pharmaceuticals Ltd | 2.62bn | -52.21m | 7.16bn | 51.00 | -- | -- | -- | 2.73 | -5.30 | -5.30 | 255.76 | -- | -- | -- | -- | 51,400,510.00 | -- | 31.86 | -- | 46.07 | 42.45 | 32.28 | -1.99 | 15.43 | -- | -- | -- | -- | 20.42 | -- | -3.56 | -- | 314.83 | -- |
| Pharmaniaga Berhad | 60.51bn | -1.38bn | 7.81bn | 3.78k | -- | -- | -- | 0.1291 | -0.0572 | -0.0572 | 2.55 | -0.2056 | 1.82 | 4.59 | 9.57 | -- | -4.06 | -6.88 | -- | -38.45 | 9.04 | 6.64 | -2.23 | -3.66 | 0.2762 | 1.37 | 1.29 | -- | -3.02 | 7.38 | 87.25 | -- | 23.35 | -- |
| Sopharma Trading AD | 77.83bn | 1.35bn | 9.36bn | 2.62k | 6.92 | 1.64 | 3.30 | 0.1203 | 0.8521 | 0.8521 | 49.05 | 3.59 | 2.77 | 0.1565 | 7.98 | 642,620.80 | 4.80 | 2.39 | 14.54 | 7.88 | 98.04 | 98.09 | 1.74 | 1.01 | 0.5952 | 187.59 | 0.615 | -- | 13.02 | 13.26 | 221.67 | 27.86 | 3.70 | -- |
| 111 Inc - ADR | 172.40bn | -4.53bn | 9.49bn | 1.66k | -- | -- | -- | 0.0551 | -0.6425 | -0.6425 | 24.55 | -0.9617 | 4.56 | 9.66 | 29.15 | -- | -10.77 | -17.09 | -- | -178.25 | 5.68 | 5.36 | -2.36 | -4.37 | 0.5457 | -32.73 | 0.5781 | -- | 10.59 | 52.95 | 5.80 | -- | -- | -- |
| EQL Pharma AB | 2.05bn | 176.55m | 9.79bn | 21.00 | 56.66 | 7.08 | -- | 4.76 | 0.7642 | 0.7642 | 8.88 | 6.12 | 0.8012 | 1.74 | 4.80 | 12,579,430.00 | 6.89 | 9.02 | 11.90 | 15.27 | 43.55 | 37.95 | 8.59 | 8.29 | 0.5694 | 8.88 | 0.4032 | -- | 1.64 | 39.64 | -26.57 | -- | 32.73 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Elara Capital Plc (Investment Management)as of 31 Mar 2023 | 950.00k | 9.19% |
